Pulmonary alveolus surface tension

Pulmonary alveolus surface tension refers to the physical force at the air-liquid interface inside lung alveoli, caused by the cohesive attraction between water molecules lining the alveolar surface[1][4][6]. This force tends to collapse the alveoli, opposing their expansion during breathing and reducing lung compliance[1][2][3][4][5]. Pulmonary surfactant, a lipid-protein complex produced by type II alveolar cells, reduces this surface tension dramatically, stabilizing alveoli of different sizes, increasing compliance, and preventing lung collapse, especially at end-expiration[2][4][5]. High surface tension, as seen in conditions with deficient surfactant (e.g., premature infants), leads to atelectasis and impaired gas exchange[2][4][6]. Therapeutic interventions target surfactant composition or replacement, not the physical phenomenon of surface tension itself. Additional notes: - "Pulmonary alveolus surface tension" is not a discrete molecular target, receptor, enzyme, or transporter; it is a biophysical phenomenon dependent on the composition of the alveolar lining fluid, primarily surfactant[1][4][5]. - Surfactant is the actual molecular complex for which drugs (natural or synthetic surfactants) are designed; such therapies treat or prevent diseases caused by increased surface tension, but do not target surface tension as a molecule or receptor itself[4][6]. - As such, this entry is marked is_incorrect: true because "Pulmonary alveolus surface tension" does not correspond to a canonical drug target and is not a molecular entity. Summary: Pulmonary alveolus surface tension represents a crucial biophysical factor in lung physiology but is not itself a molecular or pharmacological target; drugs act upon the molecular components of surfactant to indirectly modulate this parameter[2][4][6].

Other names

Alveolar surface tensionSurface tension in lung alveoliAlveolar air-liquid surface tension